Breakthrough Asthma Therapy: WIN378 Advances to Phase 3 with Promising Twice-Yearly Dosing
September 13, 2026, 8:42 am
New asthma treatment WIN378 delivers strong Phase 2 results. This ultra-long-acting TSLP inhibitor, developed by Kelun-Biotech and Harbour BioMed, and advanced by Windward Bio, significantly improved lung function (FEV1) and reduced key inflammatory markers (FeNO, eosinophils). Its extended half-life supports convenient twice-yearly dosing, a breakthrough for patient compliance. Phase 3 trials are actively underway, signaling a major advance for severe and moderate-to-severe asthma patients globally. The drug proved well-tolerated, with favorable safety results. This promising therapy targets TSLP, a critical pathway in immunological diseases, potentially transforming chronic respiratory care with fewer injections and sustained efficacy.
A new era in asthma management is emerging. WIN378, an ultra-long-acting therapeutic, shows immense promise. Positive Phase 2 trial results confirm its potential. This novel drug offers new hope for millions. Uncontrolled moderate-to-severe asthma burdens patients daily. Current treatments often demand frequent administration. This new approach seeks to alleviate that burden. It represents a significant step forward.
The POLARIS-1 study delivered compelling data. This global Phase 2/3 trial evaluated WIN378. It was a randomized, double-blind, placebo-controlled study. Interim analysis focused on the first 98 patients. All suffered from uncontrolled asthma. Results showed significant improvements. Lung function, measured by FEV1, increased substantially. FEV1 measures how much air a person can exhale in one second. Patients saw up to a 174 mL mean increase. Placebo-adjusted increases reached 256 mL. These improvements were statistically significant. They occurred rapidly. Effects were sustained through 24 weeks after a single dose.
Key biomarkers of inflammation also improved. FeNO levels decreased significantly. FeNO indicates airway inflammation. Its reduction suggests decreased airway irritation. Blood eosinophil counts plummeted. Eosinophils are white blood cells. High levels link to severe asthma exacerbations. WIN378 reduced FeNO by up to 43 percent. Eosinophil counts fell by up to 51 percent. These reductions were dose-dependent. They highlight the drug's robust anti-inflammatory action. Sustained biomarker improvement signals reduced exacerbation risk.
Safety data proved highly favorable. WIN378 was well tolerated across all dose levels. No treatment-related serious adverse events occurred. Patient withdrawals due to adverse events were absent. Discontinuations from the study were also zero. Adverse events balanced evenly between active arms and placebo. Injection site reactions were minimal, less than one percent. A small percentage, two percent, developed anti-drug antibodies. Crucially, these antibodies had no impact on the drug's pharmacology. The results underscore a strong safety profile.
The drug's pharmacokinetic profile is a major advantage. WIN378 demonstrated an extended half-life. It lasted up to 75 days. This supports a revolutionary dosing schedule. Patients could receive treatment just twice a year. This significantly reduces the treatment burden. It drastically improves patient compliance. Frequent injections or daily medications pose challenges. Twice-yearly dosing simplifies chronic disease management. It offers a new level of convenience. This could transform adherence rates. Improved adherence leads to better outcomes.
WIN378 employs a unique mechanism. It is a novel, fully human monoclonal antibody. It targets thymic stromal lymphopoietin (TSLP). TSLP acts as an "alarm cytokine." Epithelial cells release it in response to allergens or irritants. TSLP then initiates a broad inflammatory cascade. It plays a pivotal role in many immunological diseases. Asthma is a prime example. WIN378 uniquely inhibits TSLP signaling. It binds to two different sites on the TSLP molecule. This interference blocks TSLP from binding to both of its co-receptors. This unique binding mode enhances potency. It extends the drug's half-life. It also silences unwanted effector functions. This precise action makes WIN378 a differentiated therapy.
The journey continues toward patient access. The first Phase 3 study has begun. It is part of the seamless POLARIS-1 design. This phase evaluates two distinct twice-yearly doses. The primary endpoint focuses on annualized asthma exacerbation rates. It targets patients with severe asthma. A second pivotal Phase 3 trial, POLARIS-2, is planned. It will commence in the first half of 2027. These trials are critical steps. They aim to confirm WIN378's efficacy and safety on a larger scale. The goal is long-term disease control.
WIN378's impact extends beyond asthma. TSLP is implicated in other chronic conditions. These include Chronic Obstructive Pulmonary Disease (COPD). It also influences chronic rhinosinusitis with nasal polyps. Eosinophilic esophagitis is another TSLP-driven disease. WIN378 is currently under evaluation in a Phase 2 SIRIUS study for COPD. This broad therapeutic potential is significant. It positions WIN378 as a versatile pipeline asset. It could address multiple unmet medical needs across respiratory and dermatologic diseases.
Global collaboration powers this innovation. Kelun-Biotech and Harbour BioMed initially co-developed the molecule (SKB378/HBM9378). They shared global rights. Windward Bio then licensed the global rights. This excluded Greater China and specific Asian countries. Windward Bio, a clinical-stage biotechnology company, specializes in ultra-long-acting antibodies. Their expertise accelerates WIN378's development. This global partnership leverages diverse strengths. It combines advanced R&D with specialized clinical development. This ensures wider patient reach.
This development marks a significant advancement. For patients battling chronic asthma, hope grows brighter. Less frequent dosing profoundly improves quality of life. It liberates patients from the burden of frequent treatments. Sustained efficacy promises better disease control. It means fewer debilitating exacerbations. WIN378 represents a potential paradigm shift. It brings closer a future with significantly fewer asthma burdens. This new therapeutic pathway offers profound and lasting promise. It could redefine respiratory medicine.
A new era in asthma management is emerging. WIN378, an ultra-long-acting therapeutic, shows immense promise. Positive Phase 2 trial results confirm its potential. This novel drug offers new hope for millions. Uncontrolled moderate-to-severe asthma burdens patients daily. Current treatments often demand frequent administration. This new approach seeks to alleviate that burden. It represents a significant step forward.
The POLARIS-1 study delivered compelling data. This global Phase 2/3 trial evaluated WIN378. It was a randomized, double-blind, placebo-controlled study. Interim analysis focused on the first 98 patients. All suffered from uncontrolled asthma. Results showed significant improvements. Lung function, measured by FEV1, increased substantially. FEV1 measures how much air a person can exhale in one second. Patients saw up to a 174 mL mean increase. Placebo-adjusted increases reached 256 mL. These improvements were statistically significant. They occurred rapidly. Effects were sustained through 24 weeks after a single dose.
Key biomarkers of inflammation also improved. FeNO levels decreased significantly. FeNO indicates airway inflammation. Its reduction suggests decreased airway irritation. Blood eosinophil counts plummeted. Eosinophils are white blood cells. High levels link to severe asthma exacerbations. WIN378 reduced FeNO by up to 43 percent. Eosinophil counts fell by up to 51 percent. These reductions were dose-dependent. They highlight the drug's robust anti-inflammatory action. Sustained biomarker improvement signals reduced exacerbation risk.
Safety data proved highly favorable. WIN378 was well tolerated across all dose levels. No treatment-related serious adverse events occurred. Patient withdrawals due to adverse events were absent. Discontinuations from the study were also zero. Adverse events balanced evenly between active arms and placebo. Injection site reactions were minimal, less than one percent. A small percentage, two percent, developed anti-drug antibodies. Crucially, these antibodies had no impact on the drug's pharmacology. The results underscore a strong safety profile.
The drug's pharmacokinetic profile is a major advantage. WIN378 demonstrated an extended half-life. It lasted up to 75 days. This supports a revolutionary dosing schedule. Patients could receive treatment just twice a year. This significantly reduces the treatment burden. It drastically improves patient compliance. Frequent injections or daily medications pose challenges. Twice-yearly dosing simplifies chronic disease management. It offers a new level of convenience. This could transform adherence rates. Improved adherence leads to better outcomes.
WIN378 employs a unique mechanism. It is a novel, fully human monoclonal antibody. It targets thymic stromal lymphopoietin (TSLP). TSLP acts as an "alarm cytokine." Epithelial cells release it in response to allergens or irritants. TSLP then initiates a broad inflammatory cascade. It plays a pivotal role in many immunological diseases. Asthma is a prime example. WIN378 uniquely inhibits TSLP signaling. It binds to two different sites on the TSLP molecule. This interference blocks TSLP from binding to both of its co-receptors. This unique binding mode enhances potency. It extends the drug's half-life. It also silences unwanted effector functions. This precise action makes WIN378 a differentiated therapy.
The journey continues toward patient access. The first Phase 3 study has begun. It is part of the seamless POLARIS-1 design. This phase evaluates two distinct twice-yearly doses. The primary endpoint focuses on annualized asthma exacerbation rates. It targets patients with severe asthma. A second pivotal Phase 3 trial, POLARIS-2, is planned. It will commence in the first half of 2027. These trials are critical steps. They aim to confirm WIN378's efficacy and safety on a larger scale. The goal is long-term disease control.
WIN378's impact extends beyond asthma. TSLP is implicated in other chronic conditions. These include Chronic Obstructive Pulmonary Disease (COPD). It also influences chronic rhinosinusitis with nasal polyps. Eosinophilic esophagitis is another TSLP-driven disease. WIN378 is currently under evaluation in a Phase 2 SIRIUS study for COPD. This broad therapeutic potential is significant. It positions WIN378 as a versatile pipeline asset. It could address multiple unmet medical needs across respiratory and dermatologic diseases.
Global collaboration powers this innovation. Kelun-Biotech and Harbour BioMed initially co-developed the molecule (SKB378/HBM9378). They shared global rights. Windward Bio then licensed the global rights. This excluded Greater China and specific Asian countries. Windward Bio, a clinical-stage biotechnology company, specializes in ultra-long-acting antibodies. Their expertise accelerates WIN378's development. This global partnership leverages diverse strengths. It combines advanced R&D with specialized clinical development. This ensures wider patient reach.
This development marks a significant advancement. For patients battling chronic asthma, hope grows brighter. Less frequent dosing profoundly improves quality of life. It liberates patients from the burden of frequent treatments. Sustained efficacy promises better disease control. It means fewer debilitating exacerbations. WIN378 represents a potential paradigm shift. It brings closer a future with significantly fewer asthma burdens. This new therapeutic pathway offers profound and lasting promise. It could redefine respiratory medicine.